Skip to main content

Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma The study aimed to demonstrate rapid and effective molecular testing on liquid-based cytology (LBC) samples for EGFR, KRAS and BRAF mutations using the Biocartis Idylla™. Rapid on-site evaluation (ROSE) LBC samples for patients with non-small cell lung carcinoma (NSCLC) or pancreatic ductal adenocarcinoma (PDAC) were tested for EGFR, KRAS and BRAF mutations based on the relevance to tumour subtype.

The BAC kindly ask that you spend 15-20 minutes in order to complete a membership survey

View survey

This survey is open to both members and non-members, and the outcomes will influence BAC strategic policy direction over the next 12-24 months.

The information will be useful in planning future ASM meetings, training events & webinars, in particular the topics you would like to see addressed. Your responses will influence the launch of a new BAC website and the format of the Cytopathology journal.

By engaging with members and non-members alike, we can determine the issues that those in cytology would like to see addressed by the BAC.

The survey will close on 5pm on 28th May 2022